Compare EDD & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDD | LAB |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.1M | 326.2M |
| IPO Year | N/A | 2008 |
| Metric | EDD | LAB |
|---|---|---|
| Price | $5.81 | $0.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 443.3K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | ★ N/A | $3.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.96 | $0.70 |
| 52 Week High | $6.18 | $1.72 |
| Indicator | EDD | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 41.70 |
| Support Level | $5.73 | $0.70 |
| Resistance Level | $6.03 | $0.94 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 16.60 | 2.72 |
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.